title: Effective 2-wk therapy for Helicobacter pylori disease in children.
abstract: Successful eradication of Helicobacter pylori infection in children has required long treatment regimens that may result in noncompliance with failure to eradicate this organism. Despite full compliance with shorter therapeutic regimens, such as amoxycillin and omeprazole for 2 wk, the H. pylori eradication rate is poor in children.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the efficacy of, and compliance with, a 2-wk treatment with metronidazole, omeprazole, and clarithromycin in eradicating H. pylori disease in children.
  
  
  METHODS
  Over a 15-month period, children diagnosed to be H. pylori positive by Steiner's stain of gastric antral biopsy specimens were treated with metronidazole, omeprazole, and clarithromycin. Follow-up upper GI endoscopy was performed 6-8 wk after completion of therapy.
  
  
  RESULTS
  Of 15 patients with H. pylori-positive antral gastritis, 11 had duodenal ulcer disease; three patients with severe abdominal pain and one with vomiting had H. pylori gastritis only. H. pylori eradication was seen in 11 of 11 (100%) patients with duodenal ulcer disease and in three of four (75%) with gastritis only; the overall success rate was 93%. Duodenal ulcer disease healed when H. pylori was eradicated in all but one patient, who at presentation had a penetrating ulcer with a duodenobiliary fistula. Fourteen of 15 patients (93%) were fully compliant, and no adverse reactions were reported.
  
  
  CONCLUSIONS
  Two weeks of therapy with metronidazole, omeprazole, and clarithromycin is effective H. pylori therapy in children. It is well tolerated, and full compliance can be achieved.
authors.affiliation: Division of Pediatric Gastroenterology, University of British Columbia, British Columbia Children's Hospital, Vancouver, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Dohil
authors.forename: D M
authors.initials: DM
authors.lastname: Israel
authors.forename: E
authors.initials: E
authors.lastname: Hassall
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000188:drug therapy; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy*; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D007223:Infant; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects; D011706:Pyloric Antrum; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D017291:Clarithromycin; D009853:Omeprazole